{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:30Z","timestamp":1762987170561,"version":"3.45.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011722","name":"Higher Education Funding Council for England","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jtocrr.2020.100093","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T12:03:47Z","timestamp":1599134627000},"page":"100093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1\u2013Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms"],"prefix":"10.1016","volume":"1","author":[{"given":"Peter W.","family":"Szlosarek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa M.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliia","family":"Pavlyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shamash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Pacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bomalaski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Moir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sheaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2020.100093_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/modpathol.2009.180","article-title":"Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases","volume":"23","author":"Klebe","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtocrr.2020.100093_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib4","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In\u00a0vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/0008-5472.CAN-13-1702","article-title":"Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging","volume":"74","author":"Allen","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumors fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2020.100093_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","article-title":"Rewiring urea cycle metabolism in cancer to support anabolism","volume":"18","author":"Keshet","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2020.100093_bib8","first-page":"5443","article-title":"PEGylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in\u00a0vitro and in\u00a0vivo","volume":"62","author":"Ensor","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","article-title":"PEGylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in\u00a0vitro and in\u00a0vivo proliferation of human hepatocellular carcinoma through arginine depletion","volume":"67","author":"Cheng","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4143\/crt.2013.45.4.251","article-title":"Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges","volume":"45","author":"Phillips","year":"2013","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jtocrr.2020.100093_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with PEGylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib12","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of PEGylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.celrep.2016.06.097","article-title":"Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1","volume":"16","author":"Locke","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtocrr.2020.100093_bib14","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1158\/1535-7163.MCT-09-0794","article-title":"Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc\/HIF-1alpha\/Sp4","volume":"8","author":"Tsai","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtocrr.2020.100093_bib15","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2012.106","article-title":"Negative argininosuccinate synthetase expression in melanoma tumors may predict clinical benefit from arginine-depleting therapy with PEGylated arginine deiminase","volume":"106","author":"Feun","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2020.100093_bib16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1165\/rcmb.2011-0195OC","article-title":"Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells","volume":"46","author":"Battisti","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jtocrr.2020.100093_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2011.12.005","article-title":"Cancer-related inflammation: common themes and therapeutic opportunities","volume":"22","author":"Balkwill","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib19","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2020.100093_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1535-7163.MCT-07-0579","article-title":"Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma","volume":"7","author":"Miselis","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtocrr.2020.100093_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1586\/14737140.2014.911089","article-title":"Central nervous system toxicities of chemotherapeutic agents","volume":"14","author":"Peddi","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jtocrr.2020.100093_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtocrr.2020.100093_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2020.100093_bib24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [published correction appears in Lancet. 2016;387:e24]","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2020.100093_bib25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtocrr.2020.100093_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/his.13392","article-title":"The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma","volume":"72","author":"Chou","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.jtocrr.2020.100093_bib27","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0021-9258(17)42251-4","article-title":"Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. Implications for regulation of nitric oxide production","volume":"269","author":"Nussler","year":"1994","journal-title":"J\u00a0Biol Chem"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2020.100093_bib29","article-title":"Abstract B33: expansion study of PEGylated arginine deiminase (ADI-PEG 20), pemetrexed, and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer (TRAP)","volume":"24","author":"Phillips","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib30","series-title":"Tumour-Associated Macrophages","first-page":"77","article-title":"Arginine metabolism and tumour associated macrophages","author":"Phillips","year":"2012"},{"key":"10.1016\/j.jtocrr.2020.100093_bib31","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) [published correction appears in Autophagy. 2016;12:443. Selliez, Iban [corrected to Seiliez, Iban]]","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.jtocrr.2020.100093_bib33","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1158\/1078-0432.CCR-18-3729","article-title":"A\u00a0phase I study of PEGylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma","volume":"25","author":"Hall","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib34","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/0008-5472.CAN-08-3157","article-title":"Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib35","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1038\/cddis.2012.83","article-title":"Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis","volume":"3","author":"Delage","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtocrr.2020.100093_bib36","doi-asserted-by":"crossref","first-page":"58948","DOI":"10.18632\/oncotarget.19564","article-title":"PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration","volume":"8","author":"Brin","year":"2017","journal-title":"Oncotarget"},{"issue":"supple15","key":"10.1016\/j.jtocrr.2020.100093_bib37","article-title":"A\u00a0phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers","volume":"36","author":"Chang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib41","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib42","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtocrr.2020.100093_bib43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fimmu.2017.00093","article-title":"Arginine metabolism in myeloid cells shapes innate and adaptive immunity","volume":"8","author":"Rodriguez","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ni.3323","article-title":"Amino acid auxotrophy as a system of immunological control nodes","volume":"17","author":"Murray","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtocrr.2020.100093_bib45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41568-019-0106-z","article-title":"Immune control by amino acid catabolism during tumorigenesis and therapy","volume":"19","author":"Lemos","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2020.100093_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","article-title":"Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures","volume":"174","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jtocrr.2020.100093_bib47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtocrr.2020.100093_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1535-7163.MCT-12-0529","article-title":"Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis","volume":"12","author":"Sharma","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtocrr.2020.100093_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtocrr.2020.100093_bib50","article-title":"The \u201cdon\u2019t eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Sch\u00fcrch","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtocrr.2020.100093_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtocrr.2020.100093_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320301399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320301399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:35:40Z","timestamp":1762986940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364320301399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2666364320301399"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100093","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1\u2013Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100093"}}